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Abstract 
We have analyzed the surface distribution and functional expression of the insulin-like growth factor I (IGF-I) receptor and the 
IGF-II/cation-independent mannose 6-phosphate r ceptor (IGF-II/CI-MPR) in the polarized human colon adenocarcinoma cell line, 
Caco-2. Domain-selective biotinylation of the apical and basolateral surfaces of Caco-2 cells grown on filter supports revealed a 3-4-fold 
enrichment of these receptors on basolateral membranes. In addition, the biotinylation studies revealed the presence of the cation-depen- 
dent MPR on both membrane surfaces, with a 3.4-fold enrichment on basolateral membranes. Binding of ~25I-IGF-I at 4°C confirmed 
similar higher levels of expression of the IGF-I receptor at the basolateral surface than at the apical surface. Cell surface-specific binding 
of the iodinated lysosomal enzyme /3-glucuronidase was detected at 4°C on both plasma membrane domains. However, significant uptake 
of /3-glucuronidase at37°C was observed only from the basolateral surface. These results indicate that the MPRs and the IGF-I receptor 
are expressed in a polarized fashion in Caco-2 cells and that the IGF-II/CI-MPR present on apical membranes, unlike the 
IGF-II/CI-MPR expressed on the basolateral surface, is not functional in endocytosing lysosomal enzymes. 
Keywords: Mannose 6-phosphate r ceptor; Insulin-like growth factor: Insulin-like growth factor receptor; Caco-2 cell 
1. Introduction 
Insulin-like growth factors (IGFs) I and II are polypep- 
tide hormones that exert insulin-like metabolic and 
growth-promoting effects on a variety of tissues through 
their interaction with specific receptors (for reviews, see 
[1,2]). The IGF-I receptor, like the structurally homologous 
insulin receptor, is a tetrameric glycoprotein composed of 
two disulfide-linked a/3 dimers [3]. The a subunit 
(molecular mass ~ 135 kDa) is entirely extracellular and 
contains the ligand binding site whereas the /3 subunit 
(molecular mass ~ 90 kDa) is a transmembrane protein 
Abbreviations: IGF-I, insulin-like growth factor I; IGF-IL insulin-like 
growth factor II; Man-6-P, mannose 6-phosphate; MPR, mannose 6-phos- 
phate receptor; IGF-II/CI-MPR, IGF-II/cation-independent MPR; CD- 
MPR, cation-dependent MPR; DSS, disuccinimidyl suberate; S-NHS-bio- 
tin, sulfosuccinimidobiotin; DMEM. Dulbecco's modified Eagle's 
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that contains a cytoplasmic tyrosine kinase domain. Bind- 
ing of ligand to the IGF-I receptor activates the tyrosine 
kinase domain of the /3 subunit [4]. In contrast, the ~ 300 
kDa membrane-bound IGF-II/cation-independent man- 
nose 6-phosphate receptor ( IGF- I I /CI -MPR) is composed 
of a single polypeptide chain, the vast majority of which is 
exposed extracellularly, and lacks tyrosine kinase activity. 
In mammalian cells, the IGF- I I /CI -MPR binds two dis- 
tinct ligands with high affinity, IGF-II and mannose 6- 
phosphate (Man-6-P) residues on Asn-linked oligosaccha- 
rides of lysosomal enzymes (for recent review, see [5]). 
The ability to bind lysosomal enzymes via their Man-6-P 
recognition marker is shared by a second MPR, the ~ 46 
kDa cation-dependent MPR (CD-MPR), that does not bind 
IGF-II [6,7]. 
In the presence of ligand, cell surface IGF-I receptors 
are internalized to an intracellular pool, an effect which is 
reversed upon removal of the ligand [8,9], and IGF-I is 
subsequently targeted for degradation [10]. It is well estab- 
lished that the targeting of lysosomal enzymes to lyso- 
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somes can occur by either of two pathways (for reviews, 
see [5,11,12]). The major route is the biosynthetic pathway 
in which IGF-II/CI-MPRs transport newly synthesized 
lysosomal enzymes from the trans Golgi network to acidi- 
fied late endosomes where the lysosomal enzymes are 
released for packaging into lysosomes and the receptors 
are then recycled back to the Golgi. In the endocytic 
pathway, the IGF-II/CI-MPR binds and internalizes extra- 
cellular lysosomal enzymes or IGF-II from the cell surface, 
resulting in the delivery of these ligands to the lysosome 
[13]. At steady state, the majority of the IGF-II/CI-MPR 
is present in late endosomes while a small fraction ( < 10%) 
is found on the plasma membrane [14,15]. The CD-MPR 
appears to have a similar intracellular distribution and 
trafficking pattern as the IGF-II/CI-MPR [15,16]. How- 
ever, unlike the IGF-II/CI-MPR, the CD-MPR is ex- 
tremely inefficient in binding and internalizing exogenous 
lysosomal enzymes [ 17,18]. 
Previous studies have described the existence of IGF-I, 
IGF-II, and the IGF receptors in gastrointestinal epithelium 
[19,20]. However, little information is available on the 
subcellular localization and functional expression of IGF 
receptors or MPRs in polarized epithelial cells. In order to 
address this issue, we have investigated the expression of 
IGF receptors and MPRs in the well-characterized human 
colon adenocarcinoma cell line, Caco-2. After confluence, 
Caco-2 cells exhibit morphological nd functional charac- 
teristics of intestinal absorbing cells [21]. Their ability to 
grow into a polarized monolayer, composed of distinct 
apical and basolateral surfaces eparated by tight junctions, 
on permeable filter supports has allowed Caco-2 cells to be 
used in numerous intestinal transport studies and in studies 
characterizing the intracellular sorting of proteins destined 
for the apical or basolaterat membrane ([22] and references 
therein). In this report, we have utilized both domain-selec- 
tive biotinylation and ligand binding studies to determine 
the surface distribution and functional expression of the 
IGF-II/CI-MPR and the IGF-I receptor in Caco-2 cells. 
Our results show that the majority of cell surface IGF- 
II/CI-MPRs and IGF-I receptors are localized at the baso- 
lateral membrane of Caco-2 cells. Although there is a 
significant amount of the IGF-II/CI-MPR on the apical 
membrane, the receptor can internalize lysosomal enzymes 
only from the basolateral surface. In addition, our studies 
also demonstrate he synthesis and basolateral enrichment 
of CD-MPRs in Caco-2 cells. A preliminary report of these 
findings has been published [23]. 
2. Materials and methods 
2.1. Materials 
The following reagents were obtained commercially as 
indicated: EN3HANCE and EXPRE35S35S 3SS-protein la- 
beling mix which contains ~ 70% [35S]methionine and 
~ 20% [35S]cysteine (1200 Ci/mmol, DuPont-New Eng- 
land Nuclear), Na125I, cartier-free (Amersham), protein 
A-Sepharose and lactoperoxidase (Sigma), Immobilon-P 
transfer membrane (Millipore), human recombinant IGF-I 
(Upstate Biotechnology or Bachem), Bio-Rad protein as- 
say (Bio-Rad), Dulbecco's modified Eagle's medium 
(DMEM), trypsin-EDTA, and streptavidin (Gibco-BRL 
Life Technologies), disuccinimidyl suberate (DSS), and 
sulfosuccinimidobiotin (S-NHS-biotin) (Pierce), fetal 
bovine serum (HyClone Laboratories). Caco-2 cells [21] 
were kindly provided by Dr. Ward Olsen of Veterans 
Administration Hospital (Madison, WI, USA). L-MPR 13- 
2-1, MTX 3.2 cells over-expressing human /3-glucuroni- 
dase were generously provided by Dr. William S. Sly of 
St. Louis University Medical School (St. Louis, MO, 
USA). Phosphomannan from Hansenula holstii was a gift 
of Dr. M.E. Slodki of the Northern Regional Research 
Center (Peoria, IL, USA). 
2.2. Cell culture 
Caco-2 cells (passages 76-90) were grown in DMEM 
(25 mM glucose) supplemented with 20% heat-inactivated 
fetal bovine serum, 4 mM glutamine, 100 U/ml penicillin, 
and 100 /zg/ml streptomycin i  a humidified atmosphere 
containing 5% CO 2. Confluent monolayers were subcul- 
tured every 7 days by treatment with 0.05% trypsin and 
0.53 mM EDTA in phosphate-buffered saline (PBS). For 
polarity experiments, cells were grown as epithelial layers 
by high density seeding (1.5. l 0  6 cells/tilteD onto nitro- 
cellulose membrane filter inserts (Millicell-HA, 30 mm 
diameter, 0.45 /.tm pore size, Millipore). The formation 
and integrity of monolayers were assessed by the develop- 
ment of a significant ransepithelial electrical resistance, 
which increased from ~ 360 12 cm 2 to a maximum of 
~ 700 12 cm z 3 days and 14 days, respectively, after 
plating (values were measured with a Millicell-ERS 
voltohmmeter (Millipore) and were corrected for the resis- 
tance of filter inserts alone). All polarity studies were 
performed 14 days after plating. For uptake studies using 
radiolabeled ligands, only those monolayers showing per- 
meability of < 3% for the radiolabeled ligand were uti- 
lized. Labeling of Caco-2 cells with EXPRE35S35S 35S- 
protein labeling mix (50-100 /.tCi/ml) was performed in 
methionine-free DMEM containing 10% heat-inactivated 
fetal bovine serum for 16-20 h. In some experiments, cells 
were solubilized in buffer containing Triton X-100 (1%, 
v/v) and sodium deoxycholate (0.1%, w/v). To purify the 
MPRs, the resulting cell lysate was subjected to pentaman- 
nosyl phosphate-agarose affinity chromatography as de- 
scribed previously [24]. 
2.3. Immunoprecipitations 
Cell lysate or affinity column fractions were incubated 
at 4°C for 16-24 h with protein A-Sepharose plus one of 
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the following antibodies: mouse anti-human IGF-I receptor 
a-subunit monoclonal ntibody (a IR-3), 0.33-1.0 /zg/ml 
(Oncogene Science) plus rabbit anti-mouse IgG polyclonal 
antibody, 0.33-1.0 /xg/ml (ICN Biomedicals), rabbit 
anti-human i sulin receptor c~-subunit polyclonal antibody, 
0.5 /zg/ml (Upstate Biotechnology) or anti-MPR poly- 
clonal antibodies (1:1000 dilution) [24]. Following recov- 
ery by centrifugation, protein A-Sepharose beads were 
washed four times with buffer containing 0.1 M "Iris (pH 
8.0), 0.1 M NaCI, 10 mM EDTA, and 1% Triton X-100 
and once in buffer containing 20 mM Tris (pH 8.0) and 20 
mM NaC1. Bound proteins were eluted by the addition of 
Laemmli sample buffer. 
2.4. Iodination of ligands 
Human recombinant IGF-I was iodinated as described 
previously [25] to specific activities of 50-100 /zCi/p.g. 
Human fl-glucuronidase was purified from collections of 
serum-free conditioned medium from the cell line L-MPR 
13-2-1 MTX 3.2, which is known to over-express and 
secrete human fl-glucuronidase, by chromatography on an 
IGF-II/CI-MPR affinity column [26]. The specific activity 
of the purified /3-glucuronidase was 544 U//~g as deter- 
mined using p-nitrophenyl fl-o-glucuronide as the sub- 
strate [27]. /3-Glucuronidase (20 /xg) was iodinated with l 
mCi of Na125I using soluble lactoperoxidase as described 
by Jadot et al. [26] except hat following gel filtration on 
Sephadex G-150, t25I-/3-glucuronidase was further purified 
on an IGF-II/CI-MPR affinity column. The purified /3- 
glucuronidase was then dialyzed exhaustively against PBS 
to remove Man-6-P and its specific radioactivity (1.5-7.0 
~Ci//xg) was determined using p-nitrophenyl-/3-o- 
glucuronide as the substrate [27]. Streptavidin (50/zg) was 
iodinated using Iodogen as recommended by the manufac- 
turer (Pierce), and separated from NalZSI on a Sephadex 
G-25 column equilibrated in l0 mM NaPO 4 (pH 7.2), and 
150 mM NaC1. Assuming 80% recovery, the specific 
radioactivity of the streptavidin was 3.8-6.2 /~Ci//~g. 
Protein concentrations were determined using the Bradford 
assay with bovine serum albumin (BSA) as the standard 
[28]. 
2.5. Cell surface biotinylation 
Biotinylation of cell surface proteins was carried out by 
adding S-NHS-biotin (0.5 mg/ml) to the apical or basolat- 
eral compartments of filter-grown Caco-2 monolayers (14 
day growth) and was performed a total of three times for 
20 min each at 4°C in PBS containing 0.1 mM CaCI 2 and 
1.0 mM MgC1 [29]. The cells were then washed and the 
reaction quenched 6 times in PBS containing 0.1 mM 
CaCI 2, 1.0 mM MgC1, and 50 mM glycine (5 min each) at 
4°C [30]. Following removal from the filter membrane, the 
cells were solubilized in detergent and subjected to either 
pentamannosyi phosphate-agarose chromatography or im- 
munoprecipitation. 
2.6. Streptacidin blotting 
Samples biotinylated with S-NHS-biotin, after either 
immunoprecipitation r purification by pentamannosyl 
phosphate-agarose affinity chromatography, were sub- 
jected to SDS-PAGE under reducing conditions using the 
buffer conditions of Laemmli [31] and transferred to Im- 
mobilon-P using the conditions described by Burnette [32]. 
Immobilon-P membranes were blocked in PBS containing 
0.5% Tween-20, 10% glycerol (v/v), 1.0 M glucose, 2% 
nonfat dry milk (Carnation), and 3% BSA for 2 h. After 
incubation with 12~I-streptavidin (6.0. 10 7 cpm/blot) in 
PBS containing 0.5% Tween-20, 10% glycerol (v/v), 1.0 
M glucose, and 0.3% BSA for 2 h, the blots were washed 
(six times for 5 min each) in PBS plus 0.5% Tween-20 and 
dried [29]. Biotinylated proteins were visualized by auto- 
radiography at -70°C using Kodak XAR-5 film and 
Cronex Lightning Plus intensifying screens (DuPont). To 
quantify the amount of biotinylated proteins, radiolabeled 
receptor bands were excised from membranes and the 
radioactivity of the bound 125I-streptavidin was measured 
using a T-counter. The results were then normalized to 
total protein. 
2.7. Surface binding of 1251-1GF-I and t251-fl-glucuroni- 
dase 
Caco-2 cells grown on filters were prepared for ligand 
binding studies with :25I-/3-glucuronidase by a 5 min 
incubation with 10 mM Man-6-P in PBS at 4°C to dissoci- 
ate any endogenous lysosomal enzymes. Caco-2 cells were 
incubated for 10 min with an acidic pH buffer (12 mM 
citrate phosphate, pH 5.0, and 0.15 M NaC1) at 4°C to 
dissociate any endogenous ligands [6,33] prior to iigand 
binding studies with ~25I-IGF-I. For all surface binding 
studies, cells were washed thoroughly with PBS. Follow- 
ing addition of iodinated ligand (0.6 nM IGF-I or 0.2 nM 
fl-glucuronidase) in serum-free DMEM containing 1% BSA 
and 20 mM Hepes (pH 7.2) to either the apical or basolat- 
eral chamber, the cells were incubated at 4°C for 24 h. To 
determine specific binding to the IGF-I receptor, 125I-IGF-I 
ligand binding studies were performed in the absence and 
presence of a IR-3, a monoclonal antibody which specifi- 
cally blocks the binding of IGF-I to the IGF-I receptor 
[34]. Preliminary experiments were performed at a range of 
t~ IR-3 concentrations to demonstrate that maximum inhibi- 
tion of ~25I-IGF-I binding to Caco-2 cells was reached at 1 
p.g/ml (data not shown), a level consistent with that seen 
previously for maximal inhibition of IGF-I binding to the 
IGF-I receptor [34]. Identical concentrations of mouse IgG 
were used in the controls to account for any nonspecific 
effects that the presence of IgG may have on ligand 
binding. Nonspecific binding was determined in the pres- 
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Fig. I. Surface binding of iodinated ligands. Surface binding of iodinated 
IGF-I and fl-glucuronidase to Caco-2 cells grown on filters was per- 
formed as described in Section 2. Specific binding to the apical (•)  and 
basolateral (D) surface isshown as a function of time and is represented 
as a fraction of the specific binding observed atthe 40 h time point. 
ence of 10 mM Man-6-P for 125I-fl-glucuronidase binding 
studies. Incubation of Caco-2 cells with each of the ligands 
at 4°C for various times indicated that equilibrium had 
been reached by 24 h (Fig. l). Following incubation with 
ligands, apical and basolateral media were collected, pre- 
cipitated with 10% trichloroacetic acid, and the radioactiv- 
ity in the pellet and supernatant were measured separately 
in a y-counter to assay for ligand degradation. The cells 
were washed with PBS, solubilized in PBS containing 
1.0% Triton X-100 and 0.1% sodium deoxycholate, as- 
sayed for total protein, and the radioactivity measured in a 
y-counter. Specific binding was calculated by subtracting 
nonspecific binding from total binding, and two-tailed 
unpaired Student's t-tests were performed to determine 
whether the differences between their means were signifi- 
cant. 
125 2.8. Internalization of 1251-IGF-I and I-fl-glucuromdase 
Caco-2 cells grown on filters were prepared for ligand 
internalization studies in the same manner as the surface 
binding studies except that all washing and incubations 
were performed at 37°C. The iodinated ligands in serum- 
free DMEM containing 1% BSA were added to the apical 
or basolateral chamber and incubated for 2 or 6 h at 37°C. 
Nonspecific binding was determined as described in the 
above surface binding studies. Following incubation with 
ligand, the plate containing the cells on filter supports was 
placed in an ice water bath for 1 h. Apical and basolateral 
media were collected, precipitated with 10% trichloro- 
acetic acid, and the radioactivity in the pellet and super- 
natant was measured separately in a y-counter to assay for 
ligand degradation. To remove surface bound IGF-I, the 
cells were washed three times for 15 min each with PBS 
containing 1% BSA followed by three washes for 15 min 
each with an acidic pH buffer (12 mM citrate phosphate, 
pH 5.0, and 0.15 M NaCI). To remove surface bound 
/3-glucuronidase, the cells were washed three times for 15 
min each with PBS containing 1% BSA plus 10 mM 
glucose 6-phosphate followed by three washes for 15 min 
each with PBS containing 1% BSA plus 10 mM Man-6-P. 
The cells were washed three times with PBS and then 
scraped from the filter. The cells were solubilized in PBS 
containing 1.0% Triton X-100 and 0.1% sodium deoxy- 
cholate, assayed for total protein, and the radioactivity 
representing internalized ligand was measured in a y-coun- 
ter. Specific binding was calculated by subtracting nonspe- 
cific binding from total binding, and two-tailed unpaired 
Student's t-tests were performed to determine whether the 
differences between their means were significant. 
3.  Resu l ts  
3.1. Caco-2 cells synthesize IGF-H/ CI-MPRs, CD-MPRs, 
and IGF-I receptors 
To demonstrate he presence of the MPRs as well as the 
IGF-I receptor, Caco-2 cells were labeled with 
[35S]methionine/cysteine. Following labeling, the cells 
were extracted with detergent and then subjected to penta- 
mannosyl phosphate-agarose affinity chromatography. Fig. 
2A shows that Caco-2 cells synthesize proteins of ~ 230 
kDa and ~ 42 kDa that bind to the pentamannosyl phos- 
phate-agarose affinity column, corresponding to the appar- 
ent M r of the IGF-I I /CI-MPR and CD-MPR, respectively 
[5,11,12]. The absence of the proteins in the glucose 
6-phosphate eluate as well as their presence in the Man-6-P 
eluate demonstrates ligand specificity, thereby confirming 
their identity as MPRs. In addition, identical results were 
seen when immunoprecipitations of cell lysates were car- 
fled out with antibodies pecific for the MPRs (data not 
shown). In a separate experiment, detergent-solubilized 
[35S]methionine/cysteine-labeled Caco-2 cells were im- 
munoprecipitated with a monoclonal antibody specific for 
the IGF-I receptor and analyzed by SDS-PAGE. Both the 
a- and fl-subunits of the IGF-I receptor are observed at 
~ 135 kDa and ~ 90 kDa, respectively (Fig. 2B), which 
coincide with the apparent M r previously reported for this 
receptor [3]. When immunoprecipitations were performed 
with insulin receptor-specific antisera, the insulin receptor 
was observed at extremely low levels (data not shown). 
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Fig. 2. Biosynthesis of MPRs and IGF-I receptor. (a) Detergent-solubi- 
lized cell lysates from [35S]methionine/cysteine-labeled Caco-2 cells 
were passed over a pentamannosyl phosphate-agarose column. Following 
washing, the column was eluted first with 5 mM glucose 6-phosphate 
(nonspecific ligand) and then with 5 mM Man-6-P (specific ligand). The 
glucose 6-phosphate (G) and Man-6-P (M) eluates were precipitated with 
10% trichloroacetic acid and analyzed on a 10% SDS-polyacrylamide g l 
under reducing conditions. (b) Detergent-solubilized cell lysates from 
[3SS]methionine/cysteine-labeled Caco-2 cells were immunoprecipitated 
with IGF-I receptor-specific antisera (otlR-3) and analyzed on a 7.5% 
SDS-polyacrylamide g l under reducing conditions. Radiolabeled bands 
were visualized by fluorography of gels impregnated with EN3HANCE. 
The migration of molecular weight standards i indicated. 
3.2. Polarized expression of MPRs and the IGF-I receptor 
Selective labeling of apical or basolateral cell surfaces 
was performed using S-NHS-biotin, a water soluble biotin 
analog that has been shown to be impermeable to cell 
membranes and tight junctions [29]. Following biotinyla- 
tion, the MPRs and IGF-I receptor were purified, subjected 
to SDS-PAGE, and transferred to Immobilon-P mem- 
branes. The membranes were then probed with ]25I-strepta- 
vidin to visualize the biotinylated proteins. The basolat- 
eral-to-apical surface ratio for each receptor was deter- 
mined and the results are summarized in Table 1. The 
MPRs and IGF-I receptor were detected on both the apical 
and basolateral surfaces, with a basolateral enrichment of 3 
for the IGF-I I /CI-MPR (Fig. 3A), 3.4 for the CD-MPR 
(Fig. 3B), and 3.6 for IGF-I receptor (Fig. 3C). When 
biotinylated samples were immunoprecipitated with insulin 
receptor-specific antisera, insulin receptors were detected 
in levels too low to be accurately quantified (data not 
shown). 
3.3. Binding and internalization of IGF-I 
To assay for functional IGF-I receptors on the cell 
surface of Caco-2 cells, either apical or basolateral sur- 
faces of cell monolayers were exposed to iodinated ligand. 
Precipitation of conditioned medium with 10% trichloro- 
acetic acid demonstrated that there was no change (< 1%) 
in the percentage of precipitable counts from that seen for 
the iodinated ligand before incubation with the cells, indi- 
cating that no significant degradation of IGF-I had oc- 
curred during the incubation with Caco-2 cells (data not 
shown). Cells were incubated in the continual presence of 
~25I-IGF-I for either 24 h at 4°C to measure binding to cell 
surface IGF-I receptors, or for 2 h at 37°C to measure 
internalization of the ligand. Specific binding of IGF-I by 
the IGF-I receptor was determined by subtracting the 
amount bound in the presence of otlR-3, a monoclonal 
antibody which specifically blocks the binoing of IGF-I to 
the IGF-I receptor [34], from the amount of ligand bound 
in the presence of normal mouse IgG. Specific surface 
binding of 125I-IGF-I by the IGF-I receptor measured at 
4°C was 3.2-fold greater at the basolateral surface (Table 
2), a result which is consistent with the observed basolat- 
eral enrichment of the IGF-I receptor as determined by cell 
surface biotinylation studies (Table I). Specific internaliza- 
tion of 125I-IGF-I at 37°C was also observed at both 
surfaces, with a 1.2-fold greater internalization occurring 
from the basolateral surface (Table 2). Similar results were 
observed when ]25I-IGF-I binding studies were performed 
on Caco-2 cells that were not pre-washed with an acidic 
pH buffer (data not shown). To confirm that the IGF-I 
receptor was in fact mediating the binding and internaliza- 
tion of IGF-I on the cell surface, intact Caco-2 cells were 
incubated in the presence of ]25I-IGF-I at concentrations 
similar to that used in the previous binding and internaliza- 
tion studies (Table 2), and DSS, followed by preparation 
of total membranes. Analysis by SDS-PAGE indicated that 
the ot-subunit of the IGF-I receptor at ~ 135 kDa bound 
iodinated IGF-I, and this binding was effectively inhibited 
in the presence of excess unlabeled IGF-I (data not shown). 
3.4. Internalization of ~-glucuronidase occurs at the baso- 
lateral but not he apical surface 
To assay for functional IGF-I I /CI-MPRs on the cell 
surface we used a ligand specific for the IGF-II/CI-MPR. 
Iodinated /3-glucuronidase, a lysosomal enzyme, was used 
as the specific ligand following purification on an IGF- 
Table I 
Surface distribution of receptors 
Receptor Basolateral/apical a n b 
IGF-II/CI-MPR 3.0 + 0.3 4 
CD-MPR 3.4 _+ 1.0 2 
IGF-I receptor 3.6 + 0.5 ~ 4 
a Values represent the mean+S.E, of the ~25I-streptavidin measured in 
receptor bands excised from Immobilon P membranes. The radioactivity 
determined was normalized to total protein and the basolateral-to-apical 
ratio of the receptors is shown. 
b Number of independent measurements performed. 
c Values were determined by measuring the radioactivity of the ~ 135 
kDa ot-subunit of the IGF-I receptor. 
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Table 2 
Ligand binding and internalization 
cpm/mg total protein a 
cell surface b internalized c 
_ d + e specific f - -  d + e specific f 
125I-GF-I g apical (Ap) 5600 + 123 2084 +_ 90 3516 2 h: 20328 -t- 778 8061 + 302 
basolateral (BI) 15222 + 1310 4080 _+ 153 11142 2 h: 20480 + 1774 5843 _+ 414 
B1/Ap 3.2 2 h: 
125i_Glucuronidas e h apical (Ap) 2548 -t- 186 1220 _+ 212 1328 2 h: 946 _+ 112 281 _+ 33 
6h: 2553_+ 282 708_+ 69 
basolateral (Bl) 4280 + 988 1010 _+ 112 3270 2 h: 37214 -t- 5541 217 + 19 
6h: 114302_+3792 504_+ 21 
BI /Ap 2.5 2 h: 
6 h: 
12267 
14637 
1.2 
665 
1846 
36998 
113797 
55.6 
61.6 
a Values represent mean +_ S.E. Each filter of confluent, polarized Caco-2 cells contains ~ 0.3-0.4 mg total protein. 
b Experiment performed at 4°C for 24 h. 
c Experiment performed at 37°C for either 2 h or 6 h, followed by stripping of surface binding at 4°C. 
d Values represent binding in the absence of competition (for fl-glucuronidase), or in the presence of IgG (for IGF-I). 
Values represent binding in the presence of aiR-3 (IGF-I) or 10 mM Man-6-P (fl-glucuronidase). 
f Specific binding or internalization was calculated by subtracting competed values from noncompeted values (P  < 0.05 in all cases). 
g Values represent three independent measurements for cell surface and internalization studies. 
h Values represent two independent measurements for cell surface and three for internalization studies. 
I I/CI-MPR affinity column to ensure that all of the ligand 
would contain Man-6-P residues. Because the CD-MPR is 
inefficient in binding and internalizing exogenous lysoso- 
real enzymes [17,18], uptake of fl-glucuronidase would be 
due only to the IGF-II/CI-MPR. Surface-specific binding 
of /3-glucuronidase at 4°C was observed to occur at both 
surfaces with 2.5-fold greater binding at the basolateral 
surface (Table 2), which is consistent with the basolateral 
enrichment of the IGF-II/CI-MPR as determined by cell 
surface biotinylation studies (Table 1). In addition, a 55.6- 
fold greater uptake occurred from the basolateral surface 
A B C 
ap bl ap bl ap bl 
9o ; 
Fig. 3. Domain-selective labeling of Caco-2 monolayers with S-NHS-bio- 
tin. Caco-2 cells grown on filters were incubated with S-NHS-biotin 
present in either the apical (ap) or basolateral (bl) medium, solubilized 
and processed as described below. Samples were then analyzed on 9% 
SDS-polyacrylamide g ls, transferred to Immobilon-P, and biotinylated 
12S • • proteins were visualized by probing with -I-streptavldm. (a) Man-6-P 
eluate from a pentamannosyl phosphate-agarose column containing IGF- 
I I /CI-MPRs was precipitated with 10% trichloroacetic acid. (b) Follow- 
ing immunoprecipitation with IGF-II/CI-MPR-specific antisera, the cell 
lysate was subjected to pentamannosyl phosphate-agarose affinity chro- 
matography and the Man-6-P eluate containing CD-MPRs was precipi- 
tated with 10% trichloroacetic acid. (c) The run-through fraction from 
pentamannosyl phosphate-agarose affinity chromatography was immuno- 
precipitated with IGF-I receptor-specific antisera (otlR-3). The migration 
of molecular weight standards i indicated. 
when the cells were exposed to /3-glucuronidase for 2 h at 
37°C (Table 2). When the cells were exposed to fl-glucu- 
ronidase for 6 h at 37°C, three times more ligand was 
internalized than during the 2 h incubation and a similar 
(61.6-fold) greater uptake was observed from the basolat- 
eral surface. In contrast, little internalization of /3-glucu- 
ronidase was observed when the cells were exposed api- 
125 cally to I-fl-glucurontdase for either 2 h or 6 h at 37°C 
(Table 2). These results indicate that although the IGF- 
II/CI-MPR is present on both surfaces (Fig. 3A, Table 2), 
the receptor can internalize lysosomal enzymes only from 
the basolateral surface. To determine whether the lack of 
internalization atthe apical surface was due to degradation 
or removal of the Man-6-P recognition marker from ~25I- 
/3-glucuronidase, several experiments were performed. 
First, conditioned medium was precipitated with 10% tri- 
chloroacetic acid and the percentage of precipitable counts 
was found to be the same (< 3% difference) as that found 
with l~5I-fl-glucuronidase prior to incubation with the cells 
(data not shown). Second, conditioned medium was sub- 
jected to IGF-II/CI-MPR affinity chromatography. SDS- 
PAGE analysis of the column run-through and the Man-6-P 
eluates indicated that the same percentage of binding to the 
receptor column occurred as that observed for 1251-•- 
glucuronidase prior to incubation with the ceils (data not 
shown). Third, after 2 h of 37°C exposure of I25I-/3-glucu- 
ronidase to the apical or basolateral surface of Caco-2 
cells, the conditioned medium was removed, added to the 
basolateral chamber of Caco-2 cells grown on filters that 
had not been previously exposed to ligand, and incubated 
for another 2 h. The results indicated that the amount of 
125 internalized I-/3-glucuronidase from the basolateral sur- 
face was the same whether the radiolabeled ligand medium 
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was unconditioned, conditioned apically, or conditioned 
basolaterally (data not shown). Taken together, these re- 
suits demonstrate hat the lack of internalization of ~'5I-/3- 
glucuronidase at the apical surface is not due to degrada- 
tion or loss of Man-6-P from 125I-/3-glucuronidase. 
4. Discussion 
Epithelial cells are characterized by the polarized istri- 
bution of plasma membrane proteins and lipids into two 
distinct surface domains: an apical domain which faces the 
exterior of the organism and a basolateral domain which 
faces the internal environment. The tight junctions that 
separate these two domains form a barrier between the two 
environments, allowing epithelial cells to carry out a vari- 
ety of vectorial functions uch as the transport of nutrients, 
ions, and other macromolecules [35]. Since IGFs are found 
in human milk [36], saliva [37], and serum [1], intestinal 
epithelial cells are exposed to IGFs on both their apical 
and basolateral surfaces. In addition, the preferential ex- 
pression of the IGF receptors in proliferative crypt cells of 
the intestinal epithelium [19,38] suggests an important 
function for these receptors in regulating cell proliferation. 
To begin to address the roles of the IGF-I receptor and the 
IGF-II/CI-MPR in intestinal epithelial cells, we have uti- 
lized domain-selective biotinylation and ligand binding 
studies to determine the steady state surface distribution of 
these receptors in the enterocyte-like Caco-2 cell line. 
Analysis of surface biotinylated proteins revealed a 
3.6-fold enrichment of the IGF-I receptor on the basolat- 
eral surface (Fig. 3 and Table 1). Consistent with this 
finding were ligand binding studies which demonstrated a 
3.2-fold higher level of binding at the basolateral surface 
(Table 2). IGF-I binding and its subsequent uptake ob- 
served at 37°C was shown to be due solely to the IGF-I 
receptor since the specificity of binding was demonstrated 
by inhibition with a well-characterized monoclonal anti- 
body (o~IR-3) that specifically inhibits IGF-I binding to 
the IGF-I receptor [34]. In addition, only low levels of the 
insulin receptor were detected in Caco-2 cells. Thus, these 
results indicate that functional IGF-I receptors exist on 
both the apical and basolateral surface domains of Caco-2 
cells. It is unclear why the observed basolateral to apical 
ratio of IGF-I internalization (1.2, see Table 2) is not 
representative of the steady state surface levels of the 
IGF-I receptor. One possibility is that the rates of internal- 
ization of the apical and basolateral IGF-I receptors differ. 
Thus, additional experiments will be required to test this 
hypothesis. 
Surface biotinylation (Fig. 3 and Table I) and 125I-fl- 
glucuronidase binding studies (Table 2) also showed a 
3-fold and 2.5-fold, respectively, enrichment of the IGF- 
II/CI-MPR on the basolateral surface of Caco-2 cells. 
These results are consistent with the immunohistochemical 
localization of IGF-II/CI-MPRs in both the apical and 
basolateral membranes of the intact rat and human colon 
[39]. In contrast, electron microscopic immunocytochem- 
istry studies of Caco-2 cells showed that plasma membrane 
IGF-II/CI-MPRs are localized primarily to the apical do- 
main, with little or no label present on the basolateral 
surface. However, IGF-II/CI-MPRs were observed in the 
vicinity of the basolateral membrane in smooth and coated 
dense vesicles as well as in electron-lucent vesicles [40]. It 
is not clear why the earlier immunocytochemistry studies 
[40] failed to detect significant levels of the receptor on the 
basolateral surface of Caco-2 cells. One possibility is that 
the significantly greater passage number (passage 130-170) 
of the Caco-2 cell line used in the earlier study [40] caused 
subtle changes in the cells that influenced the surface 
distribution of the IGF-II/CI-MPR. It has also been ob- 
served that the surface distribution of the IGF-II/CI-MPR 
varies among different ypes of polarized cells. For exam- 
ple, the IGF-II/CI-MPR was shown by domain-selective 
labeling methods and confocal microscopy to be present 
exclusively on the basolateral surface of MDCK cells [41] 
while immunocytochemistry of rat kidney indicated an 
apical localization of the receptor in proximal tubule cells 
[42]. The functional significance of distinct patterns of 
surface expression of the IGF-II/CI-MPR in these differ- 
ent polarized epithelial cells remains to be determined. In
addition, our results also demonstrate that Caco-2 cells 
synthesize both MPRs and that the CD-MPR is enriched 
3.4-fold on basolateral membranes (Table 1). In contrast, 
the CD-MPR could not be detected on the surface of 
polarized MDCK cells [41], indicating tissue and/or cell 
type differences in the expression of the CD-MPR on the 
cell surface. Caco-2 cells have been shown to exhibit 
marked polarity with respect to plasma membrane n- 
zymes [21] and transport processes [43]. However, the 
MPRs and IGF-I receptor exhibit only a partial polariza- 
tion, as has been reported for the epidermal growth factor 
receptor which exhibits a 2.5-fold enrichment on basolat- 
eral membranes of Caco-2 cells [44]. This partial polariza- 
tion may be indicative of the need for these receptors to 
interact with their respective growth factors which are 
present in both the serum and the intestinal lumen 
[1,36,37,44]. 
Unexpectedly, our results showed that the IGF-II/CI- 
MPR expressed on the apical surface is functionally dis- 
tinct from that of the receptor expressed on the basolateral 
surface. A similar observation has been made for the EGF 
receptor expressed in Caco-2 cells. Although the EGF 
receptor is found on both apical and basolateral mem- 
branes, only the basolaterai EGF receptor increased its 
tyrosine kinase activity upon exposure to EGF [45]. Our 
results showed that Man-6-P inhibitable internalization of
the lysosomal enzyme /3-glucuronidase occurred almost 
exclusively from the basolateral side (Table 2). Analysis of 
the /3-glucuronidase in conditioned medium demonstrated 
that the lysosomal enzyme and its Man-6-P recognition 
marker were intact, ruling out preferential degradation of 
the ligand in the apical medium. Although /3-glucuroni- 
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dase is not internalized by the IGF-II/CI-MPR present on 
the apical surface, the apical receptor is capable of binding 
Man-6-P. This was demonstrated by specific binding of 
/3-glucuronidase at 4°C on the apical surface (Table 2) and 
by the observation that the receptor that had been biotinyl- 
ated on the apical surface bound to a pentamannosyl 
phosphate-agarose column (Fig. 3A). One explanation for 
these observations i  that the IGF-II/CI-MPR cannot un- 
dergo endocytosis from the apical surface. This is not a 
general feature of Caco-2 cells since IGF-I (see Table 2), 
as well as epidermal growth factor [44], can be internalized 
from the apical surface. In addition, cobalamin bound to 
intrinsic factor has been shown to undergo transcytosis 
exclusively from the apical to basolateral surface [43]. 
Impaired internalization of lysosomal enzymes has been 
observed in another intestinal epithelial cell line. A recent 
report by Braulke et al. [46] showed that the human colon 
adenocarcinoma cell line SW1116 was defective in the 
endocytosis of lysosomal enzymes, and this effect was 
attributed to a defect in the endocytosis of the IGF-II/CI- 
MPR rather than to a general defect in membrane internal- 
ization. Thus, additional studies will be required to deter- 
mine whether the IGF-II/CI-MPR expressed in apical 
membranes i  structurally different from the receptor found 
in basolateral membranes. 
In preliminary experiments, we have detected soluble, 
truncated forms of the IGF-II/CI-MPR in both the apical 
and basolateral medium of Caco-2 cells, with higher 
amounts een in the apical medium (unpublished observa- 
tion, Wick and Dahms). Thus, it is possible that the 
majority of the receptor that reaches the apical surface is 
processed for release into the apical medium. Truncated, 
soluble forms of the IGF-II/CI-MPR have been detected 
in serum [5] and have been shown to be synthesized by 
several different rat tissue explants in culture [47]. In 
addition, pulse-chase labeling experiments of several cell 
lines in culture suggest hat extracellular release into the 
medium serves as a major degradative pathway for the 
IGF-II/CI-MPR [48]. Therefore, additional experiments 
will be required to determine whether the IGF-II/CI-MPR 
is targeted to the apical surface of Caco-2 cells for subse- 
quent proteolysis and release into the medium. In addition, 
since it has been demonstrated that in Caco-2 cells protein 
sorting to the apical plasma membrane can occur either in 
the trans Golgi network prior to vesicular transport to the 
cell surface or by transcytosis after delivery to the basolat- 
eral cell surface [49], our future studies will be directed 
towards determining the route by which MPRs and IGF-I 
receptors are delivered to apical membranes. 
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